Skip to main content
Premium Trial:

Request an Annual Quote

IntegenX Raises $40M in Series C Round

NEW YORK (GenomeWeb News) – IntegenX today announced it has raised $40 million in a Series C financing round for the further development of its product pipeline and commercialization of its RapidHIT 200 Human Identification System.

Leading the round was new investor Essex Woodlands, a healthcare growth equity and venture capital firm. Existing investors Domain Associates, QuestMark Partners, Greenspring Associates, Cross Creek Capital, RONAholdings, Samsung Ventures, and strategic partner In-Q-Tel also participated in the round.

IntegenX also announced that Ronald Eastman of Essex and Benjamin Schapiro of QuestMark are joining the company's board.

The RapidHIT 200 is a sample-to-profile biometric system for real-time human DNA analysis, and according to IntegenX is the first fully automated DNA identification technology that can produce DNA profiles from buccal swabs or other human samples in less than 90 minutes. The system, it added, allows for DNA identification at the point of collection.

IntegenX expects to launch the platform and consumables system in the first half of 2012.

In October the Pleasanton, Calif.-based company and Northrop Grumman received a contract from a US army program to continue building out the RapidHIT 200 system, and in June IntegenX launched its Early Access Program for the platform, naming Key Forensic Sciences as the first international partner of the program.

Also in the company's pipeline is its Apollo 324 automated library preparation system that "relieves the next-generation sequencing bottleneck in DNA and RNA library preparation," it said.

It also is developing GenTegra and GenPlate products for stabilizing DNA, RNA, whole blood, and biological fluids for dry-state room temperature storage.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.